Phreesia's revenue rises in Q4; lowers 2027 outlook
Overview
U.S. healthcare tech firm's fiscal Q4 revenue rose 16% yr/yr, slightly beating analyst expectations
Adjusted EBITDA for fiscal Q4 beat analyst estimates, rising to $29.4 mln
Company lowered fiscal 2027 revenue outlook due to reduced pharma client spending commitments
Outlook
Phreesia lowers fiscal 2027 revenue outlook to $510 mln-$520 mln from $545 mln-$559 mln
Company maintains fiscal 2027 Adjusted EBITDA outlook at $125 mln-$135 mln
Phreesia expects AHSC growth in mid-single-digit percentage, lowers revenue per AHSC outlook to low-single-digit growth
Result Drivers
CLIENT GROWTH - Average number of healthcare services clients rose 7% yr/yr, contributing to higher revenue
PAYMENT SOLUTIONS EXPANSION - Payment solutions revenue increased, aided by the AccessOne acquisition completed in November 2025
HIGHER REVENUE PER CLIENT - Revenue per healthcare services client rose 8% yr/yr, supporting overall revenue growth
Company press release: ID:nBw2kFmLba
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Beat* | $127.07 mln | $126.62 mln (19 Analysts) |
Q4 EPS |
| $0.02 |
|
Q4 Net Income |
| $1.30 mln |
|
Q4 Adjusted EBITDA | Beat | $29.40 mln | $28.12 mln (19 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Phreesia Inc is $25.50, about 132.2% above its March 27 closing price of $10.98
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 89 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
